Technical Analysis for AXSM - Axsome Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | -1.82% | |
| Gapped Up | Strength | -1.82% | |
| 20 DMA Support | Bullish | 0.38% | |
| Crossed Above 200 DMA | Bullish | 0.38% | |
| Crossed Above 50 DMA | Bullish | 0.38% | |
| 180 Bullish Setup | Bullish Swing Setup | 0.38% | |
| Outside Day | Range Expansion | 0.38% | |
| 200 DMA Resistance | Bearish | 4.73% | |
| 50 DMA Resistance | Bearish | 4.73% | |
| Down 3 Days in a Row | Weakness | 4.73% |
| Alert | Time |
|---|---|
| Possible NR7 | about 14 hours ago |
| Down 1% | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 17 hours ago |
| Up 1% | about 18 hours ago |
| Rose Above Previous Day's High | about 18 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2024
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, develops therapies for the management and treatment of pain and other central nervous system disorders. Its product candidates include AXS-02, which is in Phase III trial for the treatment of pain in patients with complex regional pain syndrome; and AXS-05 for the treatment of agitation in patients with Alzheimer's disease and treatment resistant depression. The company is also developing AXS-02 for the treatment of knee osteoarthritis and chronic low back pain, as well as a preclinical development program AXS-06 for the treatment of chronic pain disorders. Axsome Therapeutics, Inc. was founded in 2012 and is based in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Pain Clinical Development Alzheimer's Disease Chronic Pain Pain Management Central Nervous System Disorders Depression Nervous System Disorders Knee Osteoarthritis Chronic Condition Antidepressants Treatment Of Chronic Pain Back Pain Treatment Resistant Depression
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Organ Systems Pain Clinical Development Alzheimer's Disease Chronic Pain Pain Management Central Nervous System Disorders Depression Nervous System Disorders Knee Osteoarthritis Chronic Condition Antidepressants Treatment Of Chronic Pain Back Pain Treatment Resistant Depression
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 98.4 |
| 52 Week Low | 55.0276 |
| Average Volume | 685,198 |
| 200-Day Moving Average | 74.77 |
| 50-Day Moving Average | 73.53 |
| 20-Day Moving Average | 73.36 |
| 10-Day Moving Average | 75.26 |
| Average True Range | 3.12 |
| RSI (14) | 54.55 |
| ADX | 21.82 |
| +DI | 22.70 |
| -DI | 12.73 |
| Chandelier Exit (Long, 3 ATRs) | 69.10 |
| Chandelier Exit (Short, 3 ATRs) | 74.85 |
| Upper Bollinger Bands | 79.07 |
| Lower Bollinger Band | 67.65 |
| Percent B (%b) | 0.73 |
| BandWidth | 15.57 |
| MACD Line | 0.65 |
| MACD Signal Line | 0.21 |
| MACD Histogram | 0.4424 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 80.13 | ||||
| Resistance 3 (R3) | 80.50 | 79.48 | 79.43 | ||
| Resistance 2 (R2) | 79.48 | 78.41 | 79.29 | 79.20 | |
| Resistance 1 (R1) | 77.70 | 77.75 | 77.19 | 77.33 | 78.96 |
| Pivot Point | 76.68 | 76.68 | 76.42 | 76.49 | 76.68 |
| Support 1 (S1) | 74.90 | 75.61 | 74.39 | 74.53 | 72.90 |
| Support 2 (S2) | 73.88 | 74.95 | 73.69 | 72.66 | |
| Support 3 (S3) | 72.10 | 73.88 | 72.43 | ||
| Support 4 (S4) | 71.73 |
